Advertisement
Screener

ARMATA PHARMACEUTICALS, INC. (ARMP) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

ARMATA PHARMACEUTICALS, INC. Operating Cash Flow

ARMATA PHARMACEUTICALS, INC. (ARMP) reported Operating Cash Flow of -$14.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12

  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$8.67M.
  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$5.78M.
  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$6.67M.
  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$4.30M.
  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$25.76M.
  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$37.55M.
  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$47.42M.
  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$32.48M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$8.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$14.45M
10-Q · filed 2026-08-12
-$21.12M
derived: sum of 3 quarters · filed 2026-08-12
-$25.42M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31-$5.78M
10-Q · filed 2026-05-13
-$12.46M
derived: sum of 2 quarters · filed 2026-05-13
-$16.75M
derived: sum of 3 quarters · filed 2026-05-13
-$23.96M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31-$6.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
-$10.97M
derived: sum of 2 quarters · filed 2026-03-25
-$18.18M
derived: sum of 3 quarters · filed 2026-08-12
-$25.76M
10-K · filed 2026-03-25
2025-09-30-$4.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$11.51M
derived: sum of 2 quarters · filed 2026-08-12
-$19.09M
10-Q · filed 2025-11-12
-$27.02M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30-$7.21M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$14.79M
10-Q · filed 2026-08-12
-$22.72M
derived: sum of 3 quarters · filed 2026-08-12
-$31.58M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31-$7.58M
10-Q · filed 2026-05-13
-$15.51M
derived: sum of 2 quarters · filed 2026-05-13
-$24.37M
derived: sum of 3 quarters · filed 2026-05-13
-$34.55M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31-$7.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
-$16.79M
derived: sum of 2 quarters · filed 2026-03-25
-$26.97M
derived: sum of 3 quarters · filed 2026-03-25
-$37.55M
10-K · filed 2026-03-25
2024-09-30-$8.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$19.04M
derived: sum of 2 quarters · filed 2025-11-12
-$29.62M
10-Q · filed 2025-11-12
-$37.73M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30-$10.18M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
-$20.76M
10-Q · filed 2025-08-12
-$28.87M
derived: sum of 3 quarters · filed 2025-08-12
-$38.55M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31-$10.58M
10-Q · filed 2025-05-14
-$18.69M
derived: sum of 2 quarters · filed 2025-05-14
-$28.38M
derived: sum of 3 quarters · filed 2025-05-14
-$40.44M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31-$8.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21
-$17.79M
derived: sum of 2 quarters · filed 2025-03-21
-$29.85M
derived: sum of 3 quarters · filed 2025-03-21
-$47.42M
10-K · filed 2025-03-21
2023-09-30-$9.69M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13
-$21.75M
derived: sum of 2 quarters · filed 2024-11-13
-$39.32M
10-Q · filed 2024-11-13
-$49.80M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30-$12.06M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
-$29.63M
10-Q · filed 2024-08-13
-$40.12M
derived: sum of 3 quarters · filed 2024-08-13
-$50.45M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31-$17.57M
10-Q · filed 2024-05-07
-$28.05M
derived: sum of 2 quarters · filed 2024-05-07
-$38.39M
derived: sum of 3 quarters · filed 2024-05-07
-$46.54M
derived: sum of 4 quarters · filed 2024-05-07
2022-12-31-$10.48M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21
-$20.82M
derived: sum of 2 quarters · filed 2024-03-21
-$28.97M
derived: sum of 3 quarters · filed 2024-03-21
-$32.48M
10-K · filed 2024-03-21
2022-09-30-$10.33M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
-$18.48M
derived: sum of 2 quarters · filed 2023-11-14
-$22.00M
10-Q · filed 2023-11-14
-$30.59M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30-$8.15M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
-$11.66M
10-Q · filed 2023-08-14
-$20.26M
derived: sum of 3 quarters · filed 2023-08-14
-$25.23M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31-$3.52M
10-Q · filed 2023-05-11
-$12.11M
derived: sum of 2 quarters · filed 2023-05-11
-$17.08M
derived: sum of 3 quarters · filed 2023-05-11
-$21.61M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31-$8.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16
-$13.56M
derived: sum of 2 quarters · filed 2023-03-16
-$18.10M
derived: sum of 3 quarters · filed 2023-03-16
-$23.57M
10-K · filed 2023-03-16
2021-09-30-$4.96M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
-$9.50M
derived: sum of 2 quarters · filed 2022-11-09
-$14.98M
10-Q · filed 2022-11-09
-$21.28M
derived: sum of 4 quarters · filed 2022-11-09
2021-06-30-$4.54M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
-$10.01M
10-Q · filed 2022-08-11
-$16.32M
derived: sum of 3 quarters · filed 2022-08-11
-$20.20M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31-$5.47M
10-Q · filed 2022-05-12
-$11.78M
derived: sum of 2 quarters · filed 2022-05-12
-$15.66M
derived: sum of 3 quarters · filed 2022-05-12
-$19.51M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31-$6.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
-$10.18M
derived: sum of 2 quarters · filed 2022-03-17
-$14.04M
derived: sum of 3 quarters · filed 2022-03-17
-$18.27M
10-K · filed 2022-03-17
2020-09-30-$3.88M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
-$7.74M
derived: sum of 2 quarters · filed 2021-11-10
-$11.97M
10-Q · filed 2021-11-10
-$14.70M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30-$3.86M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
-$8.09M
10-Q · filed 2021-08-12
-$10.82M
derived: sum of 3 quarters · filed 2021-08-12
-$15.38M
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31-$4.23M
10-Q · filed 2021-05-13
-$6.96M
derived: sum of 2 quarters · filed 2021-05-13
-$11.53M
derived: sum of 3 quarters · filed 2021-05-13
-$17.36M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31-$2.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18
-$7.30M
derived: sum of 2 quarters · filed 2021-03-18
-$13.12M
derived: sum of 3 quarters · filed 2021-03-18
-$15.58M
10-K · filed 2021-03-18
2019-09-30-$4.57M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12
-$10.39M
derived: sum of 2 quarters · filed 2020-11-12
-$12.85M
10-Q · filed 2020-11-12
-$16.05M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30-$5.83M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13
-$8.29M
10-Q · filed 2020-08-13
-$11.48M
derived: sum of 3 quarters · filed 2020-08-13
-$13.50M
derived: sum of 4 quarters · filed 2020-08-13
2019-03-31-$2.46M
10-Q · filed 2020-05-14
-$2.62M
10-Q · filed 2019-05-06
-$5.65M
derived: sum of 2 quarters · filed 2020-05-14
-$7.67M
derived: sum of 3 quarters · filed 2020-05-14
-$9.55M
derived: sum of 4 quarters · filed 2020-05-14
2018-12-31-$3.19M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19
-$5.21M
derived: sum of 2 quarters · filed 2020-03-19
-$7.09M
derived: sum of 3 quarters · filed 2020-03-19
-$10.63M
10-K · filed 2020-03-19
-$9.38M
10-K · filed 2019-03-25
2018-09-30-$2.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
-$3.90M
derived: sum of 2 quarters · filed 2019-11-12
-$7.43M
10-Q · filed 2019-11-12
-$6.95M
10-Q · filed 2018-11-08
-$9.80M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30-$1.88M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14
-$5.41M
10-Q · filed 2019-08-14
-$5.71M
10-Q · filed 2018-08-09
-$7.78M
derived: sum of 3 quarters · filed 2019-08-14
-$8.37M
derived: sum of 4 quarters · filed 2019-08-14
2018-03-31-$3.54M
10-Q · filed 2019-05-06
-$5.91M
derived: sum of 2 quarters · filed 2019-05-06
-$6.50M
derived: sum of 3 quarters · filed 2019-05-06
-$9.43M
derived: sum of 4 quarters · filed 2019-05-06
2017-12-31-$2.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-25
-$2.96M
derived: sum of 2 quarters · filed 2019-03-25
-$5.89M
derived: sum of 3 quarters · filed 2019-03-25
-$9.19M
10-K · filed 2019-03-25
2017-09-30-$593.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
-$3.52M
derived: sum of 2 quarters · filed 2018-11-08
-$6.82M
10-Q · filed 2018-11-08
2017-06-30-$2.93M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
-$6.23M
10-Q · filed 2018-08-09
2017-03-31-$3.30M
10-Q · filed 2018-05-15
2016-12-31-$10.61M
10-K · filed 2018-03-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22